Core Points - Indaptus Therapeutics, Inc. has entered into securities purchase agreements for a private placement of 2,109,383 shares of common stock and accompanying warrants [1][3] - The effective purchase price for each share and associated warrants is $1.065, with gross proceeds expected to be approximately $2.25 million [1][3] - The warrants will have an exercise price of $0.94 per share, are immediately exercisable, and have a term of five years [2] Financial Details - The net proceeds from the offering will be used to fund research and development activities, working capital, and general corporate purposes [3] - The offering is expected to close on or about January 15, 2025, subject to customary closing conditions [1] Regulatory Information - The shares and warrants are offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and/or Rule 506(b) of Regulation D [4] - The securities have not been registered under the Securities Act and may not be reoffered or resold in the U.S. without an effective registration statement or applicable exemption [4]

Core Insights - Indaptus Therapeutics has made significant progress in 2024, particularly with its lead clinical candidate, Decoy20, which is an innovative immunotherapy targeting cancer and viral infections [1][2] - The company has established a clinical supply agreement with BeiGene to evaluate Decoy20 in combination with tislelizumab, highlighting the potential of Decoy20 as both a standalone therapy and in synergy with existing treatments [3] - Indaptus raised $5.5 million in 2024 to support ongoing research and development efforts, ensuring financial stability for future initiatives [5] Clinical Developments - Decoy20 demonstrated a broad immune response across multiple tumor types in patients during its Phase 1 clinical trial, indicating its potential as a monotherapy [4] - The company initiated a higher-dose weekly regimen for Decoy20 after positive safety reviews, expanding the trial's scope to assess safety and efficacy [4] - Key presentations at major industry conferences, including AACR and ASCO, showcased promising preliminary results and immune activation in patients treated with Decoy20 [4] Future Outlook - Indaptus plans to advance Decoy20 through clinical trials in 2025, focusing on its combination potential with BeiGene's tislelizumab [6] - The company aims to open a combination cohort in its clinical trial and expand the number of participating clinical sites to enhance patient enrollment [9] - Upcoming milestones in the first half of 2025 are expected to represent significant advancements in the clinical development of Decoy20 and the broader Decoy platform [7] Scientific Foundation - The Decoy platform is based on a multi-targeted approach to activate both innate and adaptive immune responses, utilizing engineered Decoy bacteria to enhance therapeutic applications [8] - Pre-clinical studies have shown Decoy product candidates' effectiveness against various cancers and chronic viral infections, indicating a strong scientific foundation for future developments [10]

NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it has entered into securities purchase agreements with investors, including an officer of Indaptus, for the issuance and sale of an aggregate of 1,817,017 of its shares of common stock. In a concurrent private placement, Indaptus has also agreed to issue and sell unregistered ...

NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announced today that Dr. Michael Newman, Founder and Chief Scientific Officer, has published his groundbreaking research in the peer-reviewed journal, Frontiers in Immunology. The article, titled "Invention and Characterization of a Systemically Administered, Attenuated and Killed ...

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present at two upcoming investor conferences: BioFuture 2024 The conference is being held on October 28 – 30, 2024 at Cure by Deerfield in New York City. Presentation Date:Monday, October 28, 2024Time:3:30 PM ETTrack:12 - B (12th Floor) Mr. Meckler will be available for one-on-one meetings throughout the conference. For more information about BioFuture ...

Latest data from first and second cohorts support Company's 'pulse-prime' approach, demonstrating rapid clearance, broad immune activation, and encouraging safety profile Poster Presented at American Society of Clinical Oncology Annual Meeting NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced updated data from its ongoing Phase 1 clinical trial ...

NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces today that Jeffrey Meckler, Chief Executive Officer, and Roger Waltzman, M.D., M.B.A., Chief Medical Officer, will present a corporate overview at the Jefferies Global Healthcare Conference. The conference is being held on June 5 – 6, 2024 at the Marriott Marquis in New York City. Presentation Date: We ...

NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announces data from a poster being presented at the American Society of Clinical Oncology Annual Meeting 2024 on June 1. The conference will be held in Chicago at McCormick Place from May 31-June 4, 2024 where full data will be presented. In the abstract, titled, "Preliminary results of a Phase 1 study of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Commission File Number 001-40652 INDAPTUS THERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO | Title of each class | Trading Symbol( ...

Exhibit 99.1 Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20 NEW YORK (May 8, 2024) - Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announc ...